• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CCR8 在肿瘤内标记高度抑制性 Treg 细胞,但对于其积累和抑制功能不是必需的。

CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function.

机构信息

Department of Pathology, University of Cambridge, Cambridge, UK.

Immunology Programme, Babraham Research Campus, Babraham Institute, Cambridge, UK.

出版信息

Immunology. 2021 Aug;163(4):512-520. doi: 10.1111/imm.13337. Epub 2021 May 9.

DOI:10.1111/imm.13337
PMID:33838058
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8274197/
Abstract

CD4 regulatory T (Treg) cells, dependent upon the transcription factor Foxp3, contribute to tumour immunosuppression but are also required for immune homeostasis. There is interest in developing therapies that selectively target the immunosuppressive function of Treg cells within tumours without disrupting their systemic anti-inflammatory function. High levels of expression of chemokine (C-C motif) receptor 8 (CCR8) discriminate Treg cells within tumours from those found in systemic lymphoid tissues. It has recently been proposed that disruption of CCR8 function using blocking anti-CCR8 antibodies results in reduced accumulation of Treg cells within tumours and disruption of their immunosuppressive function. Here, using Ccr8 mice, we show that CCR8 function is not required for Treg cell accumulation or immunosuppression in the context of syngeneic MC38 colorectal adenocarcinoma and B16 melanoma tumours. We observed high levels of CCR8 expression on tumour-infiltrating Treg cells which were abolished in Ccr8 mice. High levels of CCR8 marked cells with high levels of suppressive function. However, whereas systemic ablation of Treg cells resulted in strikingly diminished tumour burden, growth of subcutaneously implanted tumours was unaffected by systemic CCR8 loss. Consistently, we observed minimal impact of systemic CCR8 ablation on the frequency, phenotype and function of tumour-infiltrating Treg cells and conventional T (Tconv) function. These findings suggest that CCR8 is not required for Treg cell accumulation and immunosuppressive function within tumours and that depletion of CCR8 Treg cells rather than blockade of CCR8 function is a more promising avenue for selective immunotherapy.

摘要

CD4 调节性 T(Treg)细胞依赖于转录因子 Foxp3,有助于肿瘤免疫抑制,但也需要免疫稳态。人们对开发能够选择性地靶向肿瘤内 Treg 细胞的免疫抑制功能而不破坏其系统性抗炎功能的治疗方法感兴趣。趋化因子(C-C 基序)受体 8(CCR8)的高表达可区分肿瘤内的 Treg 细胞与系统性淋巴组织中的 Treg 细胞。最近有人提出,使用阻断抗 CCR8 抗体破坏 CCR8 功能会导致肿瘤内 Treg 细胞积累减少,并破坏其免疫抑制功能。在这里,我们使用 Ccr8 小鼠表明,在同种异体 MC38 结直肠腺癌和 B16 黑色素瘤肿瘤的背景下,CCR8 功能对于 Treg 细胞的积累或免疫抑制并不必需。我们观察到肿瘤浸润性 Treg 细胞上高水平的 CCR8 表达,在 Ccr8 小鼠中则被消除。高水平的 CCR8 标记具有高水平抑制功能的细胞。然而,尽管系统性清除 Treg 细胞会导致肿瘤负担明显减轻,但皮下植入肿瘤的生长不受系统性 CCR8 缺失的影响。一致地,我们观察到系统性 CCR8 消融对肿瘤浸润性 Treg 细胞和常规 T(Tconv)细胞的频率、表型和功能的影响最小,并且对肿瘤浸润性 Treg 细胞和常规 T(Tconv)细胞的功能影响最小。这些发现表明 CCR8 对于肿瘤内 Treg 细胞的积累和免疫抑制功能不是必需的,并且耗尽 CCR8 Treg 细胞而不是阻断 CCR8 功能是一种更有前途的选择性免疫疗法途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d70/8274197/7a1c40015dd3/IMM-163-512-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d70/8274197/e56f4f1e332a/IMM-163-512-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d70/8274197/4c71135c5107/IMM-163-512-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d70/8274197/076f95ad16fc/IMM-163-512-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d70/8274197/558a429d6c6a/IMM-163-512-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d70/8274197/7a1c40015dd3/IMM-163-512-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d70/8274197/e56f4f1e332a/IMM-163-512-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d70/8274197/4c71135c5107/IMM-163-512-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d70/8274197/076f95ad16fc/IMM-163-512-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d70/8274197/558a429d6c6a/IMM-163-512-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d70/8274197/7a1c40015dd3/IMM-163-512-g005.jpg

相似文献

1
CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function.CCR8 在肿瘤内标记高度抑制性 Treg 细胞,但对于其积累和抑制功能不是必需的。
Immunology. 2021 Aug;163(4):512-520. doi: 10.1111/imm.13337. Epub 2021 May 9.
2
Therapeutic depletion of CCR8 tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy.CCR8 肿瘤浸润调节性 T 细胞的治疗性耗竭引发抗肿瘤免疫,并与抗 PD-1 治疗协同作用。
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001749.
3
Targeting tumor-infiltrating CCR8 regulatory T cells induces antitumor immunity through functional restoration of CD4 T and CD8 T cells in colorectal cancer.靶向肿瘤浸润性 CCR8 调节性 T 细胞通过恢复结直肠癌中 CD4 T 和 CD8 T 细胞的功能诱导抗肿瘤免疫。
J Transl Med. 2024 Jul 30;22(1):709. doi: 10.1186/s12967-024-05518-8.
4
CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory.CCR8 靶向的肿瘤组织中克隆扩增 Treg 细胞的特异性耗竭引发具有持久记忆的强烈肿瘤免疫。
Proc Natl Acad Sci U S A. 2022 Feb 15;119(7). doi: 10.1073/pnas.2114282119.
5
Blockade of TNF-α/TNFR2 signalling suppresses colorectal cancer and enhances the efficacy of anti-PD1 immunotherapy by decreasing CCR8+T regulatory cells.阻断 TNF-α/TNFR2 信号通路可抑制结直肠癌,并通过减少 CCR8+T 调节细胞来增强抗 PD-1 免疫治疗的疗效。
J Mol Cell Biol. 2024 Nov 25;16(6). doi: 10.1093/jmcb/mjad067.
6
Anti-PD-1 amplifies costimulation in melanoma-infiltrating T1-like Foxp3 regulatory T cells to alleviate local immunosuppression.抗程序性死亡蛋白1(Anti-PD-1)增强黑色素瘤浸润的T1样叉头框蛋白3(Foxp3)调节性T细胞中的共刺激,以减轻局部免疫抑制。
J Immunother Cancer. 2025 Jan 6;13(1):e009435. doi: 10.1136/jitc-2024-009435.
7
Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models.Fc 优化的抗 CCR8 抗体在人类肿瘤模型中耗竭调节性 T 细胞。
Cancer Res. 2021 Jun 1;81(11):2983-2994. doi: 10.1158/0008-5472.CAN-20-3585. Epub 2021 Mar 23.
8
CCR8FOXp3 T cells as master drivers of immune regulation.CCR8FOXp3 T 细胞作为免疫调节的主要驱动因素。
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6086-6091. doi: 10.1073/pnas.1621280114. Epub 2017 May 22.
9
CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells.CCR8:针对肿瘤浸润调节性T细胞的一个有前景的治疗靶点。
Trends Immunol. 2025 Feb;46(2):153-165. doi: 10.1016/j.it.2025.01.001. Epub 2025 Jan 30.
10
CCR8 antagonist suppresses liver cancer progression via turning tumor-infiltrating Tregs into less immunosuppressive phenotype.CCR8拮抗剂通过将肿瘤浸润性调节性T细胞转变为免疫抑制性较低的表型来抑制肝癌进展。
J Exp Clin Cancer Res. 2025 Apr 4;44(1):113. doi: 10.1186/s13046-025-03286-x.

引用本文的文献

1
Bispecific targeting of 4-1BB and CCR8 boosts antitumor immunity via Ti-Treg depletion and CD8 activation.4-1BB和CCR8的双特异性靶向通过耗尽调节性T细胞和激活CD8细胞增强抗肿瘤免疫力。
iScience. 2025 Jun 4;28(7):112829. doi: 10.1016/j.isci.2025.112829. eCollection 2025 Jul 18.
2
Emerging Immunotherapy Targets in Early Drug Development.早期药物研发中新兴的免疫治疗靶点
Int J Mol Sci. 2025 Jun 4;26(11):5394. doi: 10.3390/ijms26115394.
3
Regulatory T cells in the tumour microenvironment.肿瘤微环境中的调节性T细胞。

本文引用的文献

1
Therapeutic depletion of CCR8 tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy.CCR8 肿瘤浸润调节性 T 细胞的治疗性耗竭引发抗肿瘤免疫,并与抗 PD-1 治疗协同作用。
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001749.
2
IRF4 instructs effector Treg differentiation and immune suppression in human cancer.IRF4 指导人类癌症中效应性 Treg 的分化和免疫抑制。
J Clin Invest. 2020 Jun 1;130(6):3137-3150. doi: 10.1172/JCI130426.
3
Regulation of regulatory T cells in cancer.肿瘤微环境中调节性 T 细胞的调控。
Nat Rev Cancer. 2025 Jun 10. doi: 10.1038/s41568-025-00832-9.
4
TNFR2/CCR8 bispecific antibody enhances antitumor activity through depleting Ti-Tregs and boosting effector CD8 T cell function.肿瘤坏死因子受体2/趋化因子受体8双特异性抗体通过消耗肿瘤诱导调节性T细胞和增强效应性CD8 T细胞功能来增强抗肿瘤活性。
Oncoimmunology. 2025 Dec;14(1):2497171. doi: 10.1080/2162402X.2025.2497171. Epub 2025 Apr 28.
5
TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells.肿瘤坏死因子相关凋亡诱导配体(TRAIL)通过NFkB2途径诱导细胞因子产生,促进三阴性乳腺癌细胞中的中性粒细胞趋化和中性粒细胞介导的免疫抑制。
Cancer Lett. 2025 Jun 28;620:217692. doi: 10.1016/j.canlet.2025.217692. Epub 2025 Apr 3.
6
CCR8 antagonist suppresses liver cancer progression via turning tumor-infiltrating Tregs into less immunosuppressive phenotype.CCR8拮抗剂通过将肿瘤浸润性调节性T细胞转变为免疫抑制性较低的表型来抑制肝癌进展。
J Exp Clin Cancer Res. 2025 Apr 4;44(1):113. doi: 10.1186/s13046-025-03286-x.
7
The colorectal cancer microenvironment: Preclinical progress in identifying targets for cancer therapy.结直肠癌微环境:癌症治疗靶点识别的临床前进展
Transl Oncol. 2025 Mar;53:102307. doi: 10.1016/j.tranon.2025.102307. Epub 2025 Feb 3.
8
Chemokines that govern T cell activity in tumors.调控肿瘤中T细胞活性的趋化因子。
Curr Opin Immunol. 2025 Feb;92:102510. doi: 10.1016/j.coi.2024.102510. Epub 2024 Dec 11.
9
Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancer.Fc增强的抗CTLA-4可消耗肿瘤浸润调节性T细胞,以增强雄激素剥夺对高危前列腺癌的免疫效应。
medRxiv. 2025 Mar 31:2024.09.09.24313308. doi: 10.1101/2024.09.09.24313308.
10
Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance.探讨免疫微环境在肝细胞癌中的作用:对免疫治疗和耐药性的影响。
Elife. 2024 Aug 15;13:e95009. doi: 10.7554/eLife.95009.
Immunology. 2019 Jul;157(3):219-231. doi: 10.1111/imm.13064. Epub 2019 May 22.
4
Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.靶向 CCR8 诱导保护性抗肿瘤免疫并增强结肠癌的疫苗诱导反应。
Cancer Res. 2018 Sep 15;78(18):5340-5348. doi: 10.1158/0008-5472.CAN-18-1119. Epub 2018 Jul 19.
5
Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.CSF1R+ 巨噬细胞与 Foxp3+ Treg 细胞的补偿作用驱动肿瘤免疫治疗抵抗。
JCI Insight. 2018 Jun 7;3(11). doi: 10.1172/jci.insight.120631.
6
CCR8FOXp3 T cells as master drivers of immune regulation.CCR8FOXp3 T 细胞作为免疫调节的主要驱动因素。
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6086-6091. doi: 10.1073/pnas.1621280114. Epub 2017 May 22.
7
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells.人类组织淋巴细胞的转录图谱揭示了肿瘤浸润性调节性T细胞的独特性。
Immunity. 2016 Nov 15;45(5):1135-1147. doi: 10.1016/j.immuni.2016.10.021.
8
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer.调节性T细胞在人类乳腺癌中表现出不同特征。
Immunity. 2016 Nov 15;45(5):1122-1134. doi: 10.1016/j.immuni.2016.10.032.
9
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.Fcγ 受体调节靶向 PD-1/PD-L1 轴的抗体的抗肿瘤活性。
Cancer Cell. 2015 Sep 14;28(3):285-95. doi: 10.1016/j.ccell.2015.08.004.
10
A Distinct Function of Regulatory T Cells in Tissue Protection.调节性T细胞在组织保护中的独特功能
Cell. 2015 Aug 27;162(5):1078-89. doi: 10.1016/j.cell.2015.08.021.